 |
 |
|
|
|
|
Among the CLDT's investigations are those focusing on medical treatments to enhance liver regeneration, immunosuppressive drugs to halt the body's rejection of the new organ, and medications to prevent recurrent hepatitis following surgery.
The CLDT is one of nine centers (the only one in New York State and one of two in the Northeast) selected by the National Institutes of Health (NIH) to study living donor liver transplantation. Both the science and outcomes are being extensively analyzed by CLDT.
Phase II and III clinical trials are underway using an artificial liver device to bridge patients with liver failure to either recovery or transplantation. The CLDT is one of a selected number of centers in the nation involved in these FDA-approved trials.
The CLDT is involved in a broad range of investigations into hepatitis in adults and children, amounting to over 20 protocols. The CLDT is one of eight centers, and the only one in New York State, to investigate racial differences in response to antiviral therapy for hepatitis C with pegylated interferon and ribavirin. This study is investigating why African-Americans have shown lower response rates in prior studies, including in genetic and immunologic factors. The CLDT also is participating in NIH-sponsored studies on recurrent hepatitis B after liver transplantation and acute liver failure, as well as studies on hepatitis C, hepatitis B, and hepatitis and HIV co-infection.
The CLDT is closely associated with the Center for the Study of Hepatitis C, which is a cooperative endeavor of the Rockefeller University, Weill Medical College of Cornell University and NewYork-Presbyterian Hospital. The Center bridges the gap between basic research and patient care by combining cutting-edge efforts in research and treatment for hepatitis C, and by seeking to provide new insights into the liver disease caused by this common infection.
